Show simple item record

dc.contributor.authorWalker, JG
dc.contributor.authorMafirakureva, N
dc.contributor.authorIwamoto, M
dc.contributor.authorCampbell, L
dc.contributor.authorKim, CS
dc.contributor.authorHastings, RA
dc.contributor.authorDoussett, JP
dc.contributor.authorLe Paih, M
dc.contributor.authorBalkan, S
dc.contributor.authorMarquardt, T
dc.contributor.authorMaman, D
dc.contributor.authorLoarec, A
dc.contributor.authorCoast, J
dc.contributor.authorVickerman, P
dc.date.accessioned2020-07-11T23:01:25Z
dc.date.available2020-07-11T23:01:25Z
dc.date.issued2020-05-31
dc.date.submitted2020-07-10
dc.identifier.pmid32475010
dc.identifier.doi10.1111/liv.14550
dc.identifier.urihttp://hdl.handle.net/10144/619676
dc.description.abstractBackground & aims: In 2016, Médecins Sans Frontières established the first general population Hepatitis C virus (HCV) screening and treatment site in Cambodia, offering free direct-acting antiviral (DAA) treatment. This study analysed the cost-effectiveness of this intervention. Methods: Costs, quality adjusted life years (QALYs) and cost-effectiveness of the intervention were projected with a Markov model over a lifetime horizon, discounted at 3%/year. Patient-level resource-use and outcome data, treatment costs, costs of HCV-related healthcare and EQ-5D-5L health states were collected from an observational cohort study evaluating the effectiveness of DAA treatment under full and simplified models of care compared to no treatment; other model parameters were derived from literature. Incremental cost-effectiveness ratios (cost/QALY gained) were compared to an opportunity cost-based willingness-to-pay threshold for Cambodia ($248/QALY). Results: The total cost of testing and treatment per patient for the full model of care was $925(IQR $668-1631), reducing to $376(IQR $344-422) for the simplified model of care. EQ-5D-5L values varied by fibrosis stage: decompensated cirrhosis had the lowest value, values increased during and following treatment. The simplified model of care was cost saving compared to no treatment, while the full model of care, although cost-effective compared to no treatment ($187/QALY), cost an additional $14 485/QALY compared to the simplified model, above the willingness-to-pay threshold for Cambodia. This result is robust to variation in parameters. Conclusions: The simplified model of care was cost saving compared to no treatment, emphasizing the importance of simplifying pathways of care for improving access to HCV treatment in low-resource settings. Keywords: Markov process; cost-effectiveness; direct-acting antiviral treatment; healthcare costs; hepatitis C; low-income population; treatment costs.en_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.rightsWith thanks to Wiley.en_US
dc.subjectMarkov process
dc.subjectcost-effectiveness
dc.subjectdirect-acting antiviral treatment
dc.subjecthealthcare costs
dc.subjecthepatitis C
dc.subjectlow-income population
dc.subjecttreatment costs
dc.titleCost and cost-effectiveness of a simplified treatment model with direct-acting antivirals for chronic hepatitis C in Cambodiaen_US
dc.typeArticle
dc.identifier.eissn1478-3231
dc.identifier.journalLiver Internationalen_US
dc.source.journaltitleLiver international : official journal of the International Association for the Study of the Liver
refterms.dateFOA2020-07-11T23:01:26Z
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
Walker et al 2020 Cost and ...
Size:
893.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record